IntelliPharmaCeutics International (IntelliPharmaCeutics International) Gross-Profit-to-Asset % : 12.36% (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. IntelliPharmaCeutics International's annualized Gross Profit for the quarter that ended in Aug. 2023 was $0.20 Mil. IntelliPharmaCeutics International's average Total Assets over the quarter that ended in Aug. 2023 was $1.65 Mil. Therefore, IntelliPharmaCeutics International's annualized Gross-Profit-to-Asset % for the quarter that ended in Aug. 2023 was 12.36%.

IntelliPharmaCeutics International Gross-Profit-to-Asset % Historical Data

The historical data trend for IntelliPharmaCeutics International's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Gross-Profit-to-Asset % Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

16.83

45.14

39.03

3.74

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															4.58	8.37	86.16	115.32	12.36

Competitive Comparison of IntelliPharmaCeutics International's Gross-Profit-to-Asset %

For the Biotechnology subindustry, IntelliPharmaCeutics International's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Gross-Profit-to-Asset % falls into.

IntelliPharmaCeutics International Gross-Profit-to-Asset % Calculation

IntelliPharmaCeutics International's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Nov. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Nov. 2022 )	/	( (Total Assets (A: Nov. 2021 )	+	Total Assets (A: Nov. 2022 ))	/ count )
	=	0.066	/	( (2.096	+	1.432)	/ 2 )
	=	0.066	/	1.764
	=	3.74 %

IntelliPharmaCeutics International's annualized Gross-Profit-to-Asset % for the quarter that ended in Aug. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Aug. 2023 )	/	( (Total Assets (Q: May. 2023 )	+	Total Assets (Q: Aug. 2023 ))	/ count )
	=	0.204	/	( (1.735	+	1.566)	/ 2 )
	=	0.204	/	1.6505
	=	12.36 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Aug. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

IntelliPharmaCeutics International Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.